Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432418 | 0.76 | MAPK1 (0.54) | LMNAHPGDMAPTMEN1KMT2A | |
| SCHEMBL5635894 | 0.75 | MAPT (0.53) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL5635893 | 0.73 | MAPT (0.51) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL2990983 | 0.72 | MAPT (0.61) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL9431872 | 0.71 | LMNA (0.48) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL14074159 | 0.70 | MAPT (0.57) | NPSR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9431734 | 0.70 | NR1H3 (0.33) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL9431737 | 0.70 | NR1H3 (0.33) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL9848765 | 0.70 | MAPK1 (0.51) | NPSR1LMNAALDH1A1HPGDRXFP1 | |
| SCHEMBL10581951 | 0.70 | HPGD (0.55) | NPSR1LMNAHPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0462808-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | claimed |
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| WO-2016033164-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998041522-A9 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998044913-A2 | COMPOSITIONS CONTAINING MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | TRIANGLE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5308854-A | 2-benzoxazolylalkyl substituted pyridin-2(1H)(thi)ones; AIDS | MERCK & CO., INC. (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0462808-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | NPSR1 2044/4885LMNA 1931/4885ALDH1A1 1228/4885 |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | NPSR1 2599/4885LMNA 2797/4885ALDH1A1 3494/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | NPSR1 2044/4885LMNA 1931/4885ALDH1A1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.